About Us

About FuseBio

FuseBio is a biotechnology company focused on developing next-generation immune-modulating therapeutics designed to treat cancer by directing both innate and adaptive immunity.

We are developing immune-modifying therapies to treat cancer. Immune responses consist of multiple steps to ensure that it effectively deals with various situations within the body. FuseBio is creating therapies that potentiate two of the major categories of the immune system: innate and adaptive immunity. In this manner, FuseBio hopes to attain potent responses to danger, such as against cancerous cells, without natural breaks in the system that spare healthy tissue using their technology.

FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells.

Our Team

We have assembled a world-class team comprised of industry, clinical and academic experts, with deep knowledge in NK and T cell biology, immuno-oncology and protein engineering. The fusion of innovation and industry level development is deeply rooted in translational drug discovery and is maximized through our deep ties to renowned academic institutions. By coupling our development roadmap with our experience in clinical operations, regulatory affairs and commercialization, we have designed an effective, efficient and highly differentiated model to benefit patients in a seamless and rapid manner.